Orion Oyj/€ORNBV

05:30
08:40
11:45
14:55
18:00
1D1W1MYTD1Y5YMAX

About Orion Oyj

Orion Oyj is a Finnish pharmaceutical and diagnostics company engaged primarily in the research, development, manufacturing, and marketing of pharmaceuticals and active pharmaceutical ingredients. It operates through two main segments: the Pharmaceuticals segment, which includes proprietary drugs, specialty products, and animal health, and the Diagnostics segment, which comprises the Orion Diagnostica company focused on diagnostic tests. Founded in 1917, Orion is headquartered in Espoo, Finland, and operates globally with a significant presence in the Nordic countries and significant partnerships worldwide. Orion's strategic focus includes a strong emphasis on its proprietary drug portfolio, particularly in the central nervous system and oncology sectors, which constitutes a crucial component of its competitive strengths.

Ticker

€ORNBV
Sector

Primary listing

XHEL

Employees

3,700

Headquarters

Espo, Finland

Orion Oyj Metrics

BasicAdvanced
€9.2B
24.24
€2.69
0.38
€1.63
2.50%

Bulls say / Bears say

Net sales in Q2 2025 rose 26.9% year-on-year to EUR 416.5 million and operating profit climbed 58.9% to EUR 104.6 million, prompting Orion to raise its full-year 2025 outlook to sales of EUR 1.63–1.73 billion and operating profit of EUR 400–500 million (Orion press release )
The EMA’s CHMP gave a positive opinion on June 20, 2025 for darolutamide (Nubeqa®) in metastatic hormone-sensitive prostate cancer and the FDA approved this same indication in June 2025, further expanding Orion’s leading prostate cancer portfolio (Orion press release )
Opening a new Biologics R&D Centre in Cambridge, UK in 2025 secures access to top biotech talent and strengthens the company’s efforts in large-molecule therapies, supporting Orion’s long-term pipeline growth (Orion press release )
The shutdown of the Protein and Antibody Engineering & Characterization unit in Turku, Finland may disrupt Orion’s biologics research and development productivity and cause delays to large-molecule projects as the group winds down operations in summer 2025 (Orion press release )
Research and development costs rose by 12.0% year-on-year to EUR 90.0 million in H1 2025, putting potential pressure on margins if new clinical programs fail to deliver returns in a timely manner (Orion press release )
Interest-bearing net liabilities increased by 20.8% to EUR 134.3 million as of June 30, 2025, raising the company’s financial leverage and possibly limiting flexibility for strategic investments (Orion press release )
Data summarised monthly by Lightyear AI. Last updated on 3 Oct 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy €ORNBV

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

FAQs